$70.5 Million is the total value of NEXTHERA CAPITAL LP's 45 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PFE | New | Pfizer Inc | $10,652,000 | – | 330,000 | +100.0% | 15.11% | – |
| BMY | New | Bristol Myers Squibb Co | $10,043,000 | – | 146,000 | +100.0% | 14.25% | – |
| CELG | New | Celgene Corp | $9,581,000 | – | 80,000 | +100.0% | 13.59% | – |
| MRK | New | Merck & Co Inc New | $5,493,000 | – | 104,000 | +100.0% | 7.79% | – |
| SGEN | New | Seattle Genetics Inc | $4,039,000 | – | 90,000 | +100.0% | 5.73% | – |
| ABBV | New | AbbVie Inc | $3,643,000 | – | 61,500 | +100.0% | 5.17% | – |
| CNCE | New | Concert Pharmaceuticals Inc | $3,472,000 | – | 183,000 | +100.0% | 4.92% | – |
| HZNP | New | Horizon Pharma PLC | $3,120,000 | – | 144,000 | +100.0% | 4.43% | – |
| AGN | New | Allergan PLC | $2,875,000 | – | 9,200 | +100.0% | 4.08% | – |
| ALDR | New | Alder Biopharmaceuticals Inc | $1,982,000 | – | 60,000 | +100.0% | 2.81% | – |
| NBIX | New | Neurocrine Biosciences Inc | $1,527,000 | – | 27,000 | +100.0% | 2.17% | – |
| LBIO | New | Lion Biotechnologies Inc | $1,175,000 | – | 152,266 | +100.0% | 1.67% | – |
| FPRX | New | Five Prime Therapeutics Inc | $892,000 | – | 21,500 | +100.0% | 1.26% | – |
| New | Neuroderm Ltd | $818,000 | – | 48,000 | +100.0% | 1.16% | – | |
| CTIC | New | CTI BioPharma Corp | $807,000 | – | 656,000 | +100.0% | 1.14% | – |
| IMDZ | New | Immune Design Corp | $803,000 | – | 40,000 | +100.0% | 1.14% | – |
| AERI | New | Aerie Pharmaceuticals Inc | $688,000 | – | 28,240 | +100.0% | 0.98% | – |
| HRTX | New | Heron Therapeutics Inc | $630,000 | – | 23,600 | +100.0% | 0.89% | – |
| DRRX | New | Durect Corp | $622,000 | – | 281,514 | +100.0% | 0.88% | – |
| SCLN | New | SciClone Pharmaceuticals Inc | $598,000 | – | 65,000 | +100.0% | 0.85% | – |
| QURE | New | uniQure NV | $595,000 | – | 36,000 | +100.0% | 0.84% | – |
| ADXS | New | Advaxis Inc | $556,000 | – | 55,264 | +100.0% | 0.79% | – |
| ITEK | New | Inotek Pharmaceuticals Corp | $476,000 | – | 42,000 | +100.0% | 0.68% | – |
| ONTY | New | Oncothyreon Inc | $444,000 | – | 200,000 | +100.0% | 0.63% | – |
| INO | New | Inovio Pharmaceuticals Inc | $403,000 | – | 60,000 | +100.0% | 0.57% | – |
| VTAE | New | Vitae Pharmaceuticals Inc | $375,000 | – | 20,720 | +100.0% | 0.53% | – |
| TBRA | New | Tobira Therapeutics Inc | $352,000 | – | 35,000 | +100.0% | 0.50% | – |
| GWPH | New | GW Pharmaceuticals PLCads | $347,000 | – | 5,000 | +100.0% | 0.49% | – |
| RDHL | New | Redhill Biopharma Ltdsponsored ads | $309,000 | – | 24,000 | +100.0% | 0.44% | – |
| KMDA | New | Kamada Ltd | $302,000 | – | 72,000 | +100.0% | 0.43% | – |
| DNAI | New | Pronai Therapeutics Inc | $301,000 | – | 20,000 | +100.0% | 0.43% | – |
| PPHM | New | Peregrine Pharmaceuticals In | $287,000 | – | 245,000 | +100.0% | 0.41% | – |
| MACK | New | Merrimack Pharmaceuticals In | $284,000 | – | 36,000 | +100.0% | 0.40% | – |
| SCYX | New | SCYNEXIS Inc | $246,000 | – | 39,693 | +100.0% | 0.35% | – |
| AAAP | New | Advanced Accelerator Applicsponsored ads | $235,000 | – | 7,500 | +100.0% | 0.33% | – |
| NEOS | New | Neos Therapeutics Inc | $215,000 | – | 15,000 | +100.0% | 0.30% | – |
| NERV | New | Minerva Neurosciences Inc | $207,000 | – | 34,100 | +100.0% | 0.29% | – |
| MRNS | New | Marinus Pharmaceuticals Inc | $191,000 | – | 25,000 | +100.0% | 0.27% | – |
| VBLT | New | Vascular Biogenics Ltd | $175,000 | – | 33,332 | +100.0% | 0.25% | – |
| CPXX | New | Celator Pharmaceuticals Inc | $158,000 | – | 90,000 | +100.0% | 0.22% | – |
| ZYNE | New | Zynerba Pharmaceuticals Inc | $151,000 | – | 15,000 | +100.0% | 0.21% | – |
| CERU | New | Cerulean Pharma Inc | $140,000 | – | 50,000 | +100.0% | 0.20% | – |
| FCSC | New | Fibrocell Science Inc | $137,000 | – | 30,000 | +100.0% | 0.19% | – |
| TLOG | New | TetraLogic Pharmaceuticals C | $111,000 | – | 64,000 | +100.0% | 0.16% | – |
| GNVC | New | GenVec Inc | $35,000 | – | 19,097 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.